NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Inclusion Criteria:

• Patients with histologically confirmed, advanced-stage protocol-specified solidtumors.

• Confirmed ROR1 tumor expression.

• Patients who have undergone at least one prior systemic therapy and haveradiologically or clinically determined progressive disease during or after mostrecent line of therapy, and for whom no further standard therapy is available, orwho are intolerable or have medical contraindications to standard therapy.

Exclusion Criteria:

• Prior treatment with any agent targeting ROR1 or prior treatment with a CD3 T-cellengaging therapy.

• Prior treatment with chimeric antigen receptor (CAR) cell therapy within 90 daysprior to first dose of NM32-2668.

• Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever isshorter, prior to first dose of NM32-2668.

• Wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focalradiation for analgesic purpose or for lytic lesions at risk of fracture within 14days prior to first dose of NM32-2668, or no recovery from side effects of suchprior interventions.